321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer

MLA

Victoria Fitzpatrick, et al. “321 Phase I Clinical Trial Assessing the Combination of Systemic Chemokine Modulatory Regimen Targeting TLR3 with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.” Journal for ImmunoTherapy of Cancer, vol. 8, Nov. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8eac885bd79c9058aaf77332a546516b&authtype=sso&custid=ns315887.

APA

Victoria Fitzpatrick, Mateusz Opyrchal, Per H. Basse, Tracey O’Connor, Kristopher Attwood, Marc S. Ernstoff, Amy P. Early, Shipra Gandhi, Marie Quinn, Agnieszka K. Witkiewicz, Cayla Ford, Ellis G. Levine, Melissa J. Grimm, & Pawel Kalinski. (2020). 321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer. Journal for ImmunoTherapy of Cancer, 8.

Chicago

Victoria Fitzpatrick, Mateusz Opyrchal, Per H. Basse, Tracey O’Connor, Kristopher Attwood, Marc S. Ernstoff, Amy P. Early, et al. 2020. “321 Phase I Clinical Trial Assessing the Combination of Systemic Chemokine Modulatory Regimen Targeting TLR3 with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.” Journal for ImmunoTherapy of Cancer 8 (November). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8eac885bd79c9058aaf77332a546516b&authtype=sso&custid=ns315887.